Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
arcticnovartis
Wed, 02/18/2026 – 07:19
Read more about Novartis remibrutinib first therapy to achieve Phase III primary endpoint in ch…
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
arcticnovartis
Wed, 02/18/2026 – 07:19
Read more about Novartis remibrutinib first therapy to achieve Phase III primary endpoint in ch…
Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
arcticnovartis
Fri, 02/13/2026 – 07:19
Read more about Novartis Vanrafia® Phase III data support slowing of kidney function decline in pa…
Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
arcticnovartis
Fri, 02/13/2026 – 07:19
Read more about Novartis Vanrafia® Phase III data support slowing of kidney function decline in pa…
Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
arcticnovartis
Fri, 02/13/2026 – 07:19
Read more about Novartis Vanrafia® Phase III data support slowing of kidney function decline in pa…
Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery
arcticnovartis
Fri, 02/06/2026 – 18:03
Read more about Novartis breaks ground on new global Biomedical Research center in San Diego to accele…
Novartis erzielte im Jahr 2025 eine Umsatzsteigerung im hohen einstelligen Prozentbereich, eine Kerngewinnmarge von 40% sowie weitere Fortschritte in der Pipeline
arcticnovartis
Wed, 02/04/2026 – 07:04
Read more about Novartis erzielte im Jahr 202…
Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025
arcticnovartis
Wed, 02/04/2026 – 07:04
Read more about Novartis delivered high single-digit sales growth, achieved 40% core margi…
Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
arcticnovartis
Fri, 01/16/2026 – 18:02
Read more about Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
De…
Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment
arcticnovartis
Fri, 01/09/2026 – 16:32
Read more about Novartis to add radioligand therapy manufa…
